ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 133

Utility of PET-CT Imaging in IgG4-Related Disease

Arezou Khosroshahi1, Leslie Lee2, Mollie Carruthers1, Rusen Acu2, Pietro Bonaffini2, Vikram Deshpande3, Dushyant Sahani2 and John H. Stone1, 1Rheumatology, Massachusetts General Hospital, Boston, MA, 2Radiology, Massachusetts General Hospital, Boston, MA, 3Pathology, Massachusetts General Hospital, Boston, MA

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Immunoglobulin (IG) and positron emission tomography (PET)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Imaging of Rheumatic Diseases: Ultrasound, Nuclear Medicine and Fluorescence Imaging

Session Type: Abstract Submissions (ACR)

Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibro-inflammatory condition characterized by unique pathological features that affect a wide variety of organs.  The disease process may be active long before patients present with symptoms from the mass effect of the IgG4-related lesions or the organ damage. Morphologic and functional imaging studies are increasingly used in the diagnosis and monitoring of response to therapy in inflammatory diseases. Positron-emission tomography/computed tomography (PET/CT) enables the acquisition of whole-body images and provides functional information about disease activity. The purpose of our study was to describe the PET/CT findings in patients with histologically-proven IgG4-RD and to evaluate their correlation with disease activity.

Materials/Methods: We searched the IgG4-RD Registry at Massachusetts General Hospital. Between March 2007 and May 2012, 20 patients (7 female and 13 male; median age 57 years, range 27-81), underwent whole body 18F-fluoro-2-deoxy-D-glucose positron-emission tomography/computed tomography (FDG PET-CT) imaging. All 20 patients had diagnoses of IgG4-RD based on the characteristic histology and immunostaining findings for this condition. We compared the sites of disease activity identified by PET/CT to the sites identified by their clinicians through symptoms, signs, laboratory findings, and other imaging studies. 

Results: Patients presented with various symptoms including: flank/back pain (7 patients), face swelling (3), neck swelling (3), proptosis (2), cough (2), weight loss (2), sinus congestion (2), and dry mouth/eyes (1).  Thirteen of 20 patients (65%) had multi-organ disease at presentation, affecting some combination of the pancreas, bile ducts, liver, gallbladder, lung, salivary glands, orbitals, aorta, thyroid, kidney, retroperitoneum, and lymph nodes.  The mean number of organs involved among patients with multi-organ disease was 4.1 (ranging 2-7 organs).  Seven patients (35%) had localized disease at presentation (5 RPF, 1 lymphadenitis, 1 orbital pseudotumor).

The serum IgG4 was elevated in 8 patients at the time of PET-CT imaging (mean 635.6 mg/dL). FDG PET was positive in all 20 patients (mild to intense uptake in 19 and low in 1 subject). In 17/20 patients (85%), FDG uptake was concordant with clinical manifestations of active inflammation. In addition 7/20 patients (35%) had FDG uptake in organs not suspected of involvement on a clinical basis alone (RPF, lymph nodes, thoracic aorta, lung, lacrimal glands and nasopharynx).

Conclusion: In IgG4-RD, FDG PET-CT is a sensitive imaging tool for the detection of subclinical disease.  This modality can demonstrate additional sites of disease not obvious by clinical presentation or on conventional CT imaging, therefore providing a more complete assessment of the extent of organ disease. It’s utility as a tool for monitoring treatment response and guiding therapy requires prospective studies.


Disclosure:

A. Khosroshahi,
None;

L. Lee,
None;

M. Carruthers,
None;

R. Acu,
None;

P. Bonaffini,
None;

V. Deshpande,
None;

D. Sahani,
None;

J. H. Stone,

Genentech,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/utility-of-pet-ct-imaging-in-igg4-related-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology